CRX - Project

CRX-项目

基本信息

批准号：
10554405
负责人：
Craig Lee Slingluff
金额：
$ 4.68万
依托单位：
UNIVERSITY OF VIRGINIA
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-09-16 至 2027-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10554405
关键词：
Adoptive Cell Transfers Advisory Committees American College of Radiology Imaging Network Biomedical Engineering Biostatistics Shared Resource Bispecific Antibodies Breast Cancer Biology Cancer Burden Cancer Center Cancer Center Support Grant Catchment Area Chest Clinic Clinical Investigator Clinical Research Clinical Trials Clinical Trials Cooperative Group Collaborations Colorectal Combined Modality Therapy Cyclic GMP Diagnosis Direct Costs Disease Drug Delivery Systems Early Therapeutic-Clinical Trials Network Eastern Cooperative Oncology Group Encapsulated Engineering Epigenetic Process Exposure to Focused Ultrasound Funding Goals Grant Image Immunologics Immunomodulators Immunooncology Immunotherapeutic agent Immunotherapy Incidence Infrastructure Intellectual Property Interdisciplinary Study Investments Lead Leadership Legal patent Licensing Lung Malignant Neoplasms Metastatic Prostate Cancer Metastatic malignant neoplasm to brain Molecular Molecular Genetics Paper Patients Peer Review Performance Pharmaceutical Preparations Principal Investigator Productivity Publications Publishing Research Research Personnel Schools Science Selection for Treatments Source Technology Therapeutic Therapeutic Intervention Thoracic Surgical Procedures Tissues Toxic effect Translational Research Translational trial Translations University of Virginia Cancer Center Urothelium Uterus Validation Work base biobank cancer imaging cancer immunotherapy cancer therapy cancer type chronic T-cell leukemia clinical application clinical development design image guided therapy immune imaging innovation investigator-initiated trial melanoma member mortality new technology new therapeutic target novel therapeutics pre-clinical preclinical development programs protocol development recruit research facility response small molecule small molecule therapeutics success therapeutic target translational pipeline tumor immunology tumor microenvironment working group

项目摘要

CANCER THERAPEUTICS (CRX) – PROJECT SUMMARY/ABSTRACT Recent advances offer unprecedented opportunities to create new modes of diagnosing, imaging, and treating many types of cancer. The Cancer Therapeutics (CRX) Program exists to bring together University of Virginia Cancer Center (UVACC) investigators whose multi-disciplinary research programs collectively support preclinical science, validation of therapeutic targets, and translation of discoveries into investigator-initiated clinical trials (IITs). A hallmark of the CRX program is to drive discoveries and new technologies along the Translational Pipeline to obtain the UVACC's ultimate goal of reducing the burden of cancer in the catchment area and beyond. In addition to identifying immune therapeutic targets and developing immunotherapies (Aim 1), CRX advances other therapeutic and imaging discoveries, including those from the Cancer Biology (CBIO) and Molecular Genetics and Epigenetics (GEN) Programs through preclinical development (Aim 2) culminating in the initiation and performance of investigator-initiated clinical trials (IITs) of agents developed by UVA investigators (Aim 3). The CRX program is led by three co-leaders (Slingluff, Kelly, Landen) with complementary expertise in discovery science, translation, and clinical trials. The Program consists of 59 Members, 29 of whom are new to UVA or the UVACC since the prior renewal, from 16 departments and two schools. CRX Program Members lead the newly created Translational Research Teams, which facilitate the productive collaboration of members from all Programs to focus research efforts on four cancers identified to be particularly burdensome within the catchment area. CRX Members are principal investigators of grants totaling $5.54M of direct-cost peer-reviewed funding, $3.85M from NCI and $1.69M from other peer-reviewed sources. CRX depends on infrastructure created by the UVACC, especially the Molecular and Immunological Translational Sciences Core, Biorepository and Tissue Research Facility, Biostatistics Shared Resource, and the Office of Clinical Research. Together, these activities culminated in 407 selected publications since the last renewal. Of these, 25% have an impact factor of 10 or greater, 27% are intra-programmatic, 21% are inter- programmatic with other UVACC Programs, and 46% are collaborative with other NCI Cancer Centers.

癌症治疗 (CRX) – 项目摘要/摘要最近的进展为创建新的诊断、成像和诊断模式提供了前所未有的机会。癌症治疗 (CRX) 项目的存在是为了将癌症治疗大学联合起来。弗吉尼亚癌症中心 (UVACC) 的多学科研究项目共同支持的研究人员临床前科学、治疗靶点的验证以及将发现转化为研究者发起的临床试验 (IIT) 的一个特点是推动发现和新技术的发展。实现 UVACC 减少流域癌症负担的最终目标的转化管道除了确定免疫治疗靶点和开发免疫疗法之外（目标） 1)、CRX 推进了其他治疗和成像发现，包括来自癌症生物学 (CBIO) 的发现以及分子遗传学和表观遗传学 (GEN) 计划通过临床前开发（目标 2）达到顶峰参与由 UVA 开发的药物的研究者发起的临床试验 (IIT) 的启动和执行 CRX 项目由三位联合领导者（Slingluff、Kelly、Landen）领导。该计划包含 59 项发现科学、翻译和临床试验方面的补充专业知识。成员中，有 29 名是 UVA 或 UVACC 自上次更新以来的新成员，来自 16 个部门和 2 个部门 CRX 项目成员领导新成立的转化研究团队，促进所有计划的成员进行富有成效的合作，将研究工作重点放在已确定的四种癌症上 CRX 成员是拨款的主要研究者。总计 554 万美元的直接成本同行评审资金，其中 385 万美元来自 NCI，169 万美元来自其他同行评审 CRX 依赖于 UVACC 创建的基础设施，尤其是分子和免疫学。转化科学核心、生物样本库和组织研究设施、生物统计学共享资源以及自上次以来，这些活动最终发表了 407 篇精选出版物。其中，25% 的影响因子为 10 或更高，27% 为程序内更新，21% 为程序间更新。与其他 UVACC 项目进行规划，46% 与其他 NCI 癌症中心合作。